Tavaborole
FDA-approved product (solution, topical), marketed as Kerydin, Tavaborole.
- Registered studies
- 11
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Tinea
- Tinea unguium
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antifungals for topical use
- FDA pharmacologic class
- Oxaborole Antifungal FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AE24; FDA class Oxaborole Antifungal
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
11registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not docked: the structure could not be prepared for dockingdetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not docked: the structure could not be prepared for dockingdetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not docked: the structure could not be prepared for dockingdetails
Dihydrofolate reductase ↗ (MRSA)
Not docked: the structure could not be prepared for dockingdetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tavaborole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
NCT03405818 · start 2015-10-22
Registered record
- Registry ID
- NCT03405818
- Conditions
- Onychomycosis; Tinea Unguium
- Interventions
- Tavaborole 5% Topical Solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-10-22
- Completion
- 2017-07-27
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosis; Tinea UnguiumInterventionTavaborole 5% Topical SolutionPhasePhase 4Registry statusCompletedEfficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01302119 · start 2011-02
Registered record
- Registry ID
- NCT01302119
- Conditions
- Onychomycosis of Toenails
- Interventions
- AN2690 Topical Solution, 5%; Solution Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2013-02-20
- Enrolment
- 604
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosis of ToenailsInterventionAN2690 Topical Solution, 5%; Solution VehiclePhasePhase 3Registry statusCompletedEfficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01270971 · start 2010-12-01
Registered record
- Registry ID
- NCT01270971
- Conditions
- Onychomycosis of Toenails
- Interventions
- AN2690 Topical Solution, 5%; Solution Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12-01
- Completion
- 2013-01-08
- Enrolment
- 594
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosis of ToenailsInterventionAN2690 Topical Solution, 5%; Solution VehiclePhasePhase 3Registry statusCompletedAbsorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
NCT00679601 · start 2007-03-31
Registered record
- Registry ID
- NCT00679601
- Conditions
- Onychomycosis
- Interventions
- AN2690
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-03-31
- Completion
- 2007-05-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosisInterventionAN2690PhasePhase 2Registry statusCompletedSafety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
NCT01278394 · start 2007-03
Registered record
- Registry ID
- NCT01278394
- Conditions
- Onychomycosis
- Interventions
- AN2690 Solution, 5.0%
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2008-07
- Enrolment
- 29
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosisInterventionAN2690 Solution, 5.0%PhasePhase 2Registry statusCompletedCumulative Irritation Test
NCT00680095 · start 2007-01-22
Registered record
- Registry ID
- NCT00680095
- Conditions
- Onychomycosis
- Interventions
- AN2690; AN2690; AN2690; AN2690 Solution, Vehicle; Sodium Lauryl Sulfate, 0.5%
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-01-22
- Completion
- 2007-02-19
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosisInterventionAN2690; AN2690; AN2690; AN2690 Solution, Vehicle +1 morePhasePhase 1Registry statusCompletedStudy of Different Doses of a Novel Treatment for Onychomycosis
NCT00679770 · start 2006-06-30
Registered record
- Registry ID
- NCT00679770
- Conditions
- Distal, Subungual Onychomycosis
- Interventions
- AN2690, 2.5%; AN2690, 5%; AN2690, 7.5%; Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-06-30
- Completion
- 2007-08-31
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDistal, Subungual OnychomycosisInterventionAN2690, 2.5%; AN2690, 5%; AN2690, 7.5%; VehiclePhasePhase 2Registry statusCompletedSafety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
NCT00680134 · start 2006-06-30
Registered record
- Registry ID
- NCT00680134
- Conditions
- Onychomycosis
- Interventions
- AN2690; AN2690
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-06-30
- Completion
- 2007-08-31
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosisInterventionAN2690; AN2690PhasePhase 2Registry statusCompletedAbsorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
NCT00680160 · start 2006-04-30
Registered record
- Registry ID
- NCT00680160
- Conditions
- Onychomycosis
- Interventions
- AN2690
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-04-30
- Completion
- 2007-05-09
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosisInterventionAN2690PhasePhase 2Registry statusCompletedStudy of Different Doses of a Novel Treatment for Onychomycosis
NCT00679965 · start 2006-02-28
Registered record
- Registry ID
- NCT00679965
- Conditions
- Distal, Subungual Onychomycosis
- Interventions
- AN2690, 2.5%; AN2690, 5%; AN2690, 7.5%; AN2690 Solution Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-02-28
- Completion
- 2007-07-31
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDistal, Subungual OnychomycosisInterventionAN2690, 2.5%; AN2690, 5%; AN2690, 7.5%; AN2690 Solution VehiclePhasePhase 2Registry statusCompletedSafety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
NCT00679523 · start 2005-11
Registered record
- Registry ID
- NCT00679523
- Conditions
- Onychomycosis
- Interventions
- AN2690 Solution, 5.0%; AN2690 Solution, 7.5%
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2007-02
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOnychomycosisInterventionAN2690 Solution, 5.0%; AN2690 Solution, 7.5%PhasePhase 2Registry statusCompleted